Discover

ACRS
Aclaris Therapeutics, Inc.
5.34
2 x 4.03
2 x 6.74
bid
ask
+
0.05
0.95%
2 @ 07:02 AM
5.38 +0.04 (0.75%)
Ytd77.41%
1y278.72%
5.24
day range
5.69
1.39
52 week range
5.69
Open5.59Prev Close5.29Low5.24High5.69Mkt Cap745.80M
Vol2.39MAvg Vol1.53MEPS-0.56P/EN/AForward P/E-5.00
Beta0.12Short Ratio0.47Inst. Own90.21%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-0650-d Avg4.59200-d Avg3.361yr Est10.00

ACRS News

Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength?
zacks.com
Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength?

Aclaris (ACRS) witnessed a jump in share price last session on above-average trading volume. The lat

12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers Alzamend Neuro (NASDAQ:ALZN) stock increased by 12.9% to $1.35 during Tuesday's after-m

SL Science Holding, Alamos Gold And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
benzinga.com
SL Science Holding, Alamos Gold And Other Big Stocks Moving Lower In Monday’s Pre-Market Session

U.S. stock futures mixed. SL Science shares fall 11.4% after reporting financial results. Other stoc

This Piper Sandler Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations From Tuesday
benzinga.com
This Piper Sandler Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations From Tuesda

Top Wall Street analysts begin coverage of Aclaris Therapeutics, Orion Group Holdings, and Take-Two

benzinga.com
Aclaris Therapeutics Q1 EPS $(0.15), Inline, Sales $1.996M Beat $1.322M Estimate

Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.15) per share which met the anal

benzinga.com
Piper Sandler Maintains Overweight on Aclaris Therapeutics, Raises Price Target to $11

Piper Sandler analyst Biren Amin maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Overweight a

This Applied Materials Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
benzinga.com
This Applied Materials Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tue

Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Cit

benzinga.com
Guggenheim Initiates Coverage On Aclaris Therapeutics with Buy Rating, Announces Price Target of $12

Guggenheim analyst Seamus Fernandez initiates coverage on Aclaris Therapeutics (NASDAQ:ACRS) with

benzinga.com
Wedbush Maintains Outperform on Aclaris Therapeutics, Raises Price Target to $10

Wedbush analyst Martin Fan maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Outperform and ra

benzinga.com
Aclaris Therapeutics Announces Top Line Results From Its Phase 1a Single And Multiple Ascending Dose

"These results validate that ATI-052 is a highly potent and well tolerated bispecific antibody t

benzinga.com
Aclaris Therapeutics to Reveal Clinical Update On Key Biologic And Oral Inhibitor Programs on April

Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on deve

benzinga.com
Oppenheimer Initiates Coverage On Aclaris Therapeutics with Outperform Rating, Announces Price Targe

Oppenheimer analyst Jeff Jones initiates coverage on Aclaris Therapeutics (NASDAQ:ACRS) with a Ou

benzinga.com
Wedbush Reiterates Outperform on Aclaris Therapeutics, Maintains $8 Price Target

Wedbush analyst Martin Fan reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Outperform and m

benzinga.com
Aclaris Therapeutics Presents Additional Results From Phase 2a Trial Of ATI-2138, Potent And Selecti

- Participants with Atopic Dermatitis Receiving ATI-2138 Experienced Improvements in Key Clinical Me

benzinga.com
Aclaris Therapeutics To Present Results From Open-Label Phase 2a Trial Of ATI-2138, Investigational

Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on deve

benzinga.com
HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $16 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS)

benzinga.com
Aclaris Therapeutics Q4 EPS $(0.16) Misses $(0.14) Estimate, Sales $1.295M Miss $1.938M Estimate

Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.16) per share which missed the a

Aclaris Therapeutics Q4 Earnings Summary & Key Takeaways
benzinga.com
Aclaris Therapeutics Q4 Earnings Summary & Key Takeaways

Looking Into Aclaris Therapeutics Inc's Recent Short Interest
benzinga.com
Looking Into Aclaris Therapeutics Inc's Recent Short Interest

benzinga.com
HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $16 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS)

Aclaris Hair Loss Drug Shows Faster Results Than Pfizer's Drug
benzinga.com
Aclaris Hair Loss Drug Shows Faster Results Than Pfizer's Drug

Aclaris Therapeutics reported early study results showing its ATI-2138 drug drove rapid and lasting

benzinga.com
Aclaris Therapeutics Announces Preclinical Results From Potent And Selective ITK/JAK3 Inhibitor ATI-

- ATI-2138 Outperforms Ritlecitinib in Reversal Model of Alopecia Universalis, the Most Severe AA Ph

benzinga.com
HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $16 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS)

12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session

benzinga.com
Aclaris Therapeutics Reveals Interim Results From the First-in-human Phase 1a Single and Multiple As

Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial Reinforce

benzinga.com
Aclaris Therapeutics Q3 EPS $(0.12) Beats $(0.14) Estimate, Sales $3.299M Beat $1.405M Estimate

Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.12) per share which beat the ana

benzinga.com
HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $16 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS)

benzinga.com
Aclaris Therapeutics To Host 2025 R&D Day In Midtown, New York On October 14 To Discuss Its Progress

Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on deve

benzinga.com
Aclaris Therapeutics' ATI-2138 Phase 2a Trial Results To Be Presented At 2025 EADV Congress In Paris

- Late Breaking Abstract to Present Additional Data from Aclaris' Phase 2a Trial of ATI-2138 in

Stock Market Today: US Future Edge Higher Ahead Of FOMC Decision—Meta, Microsoft Earnings In Focus
benzinga.com
Stock Market Today: US Future Edge Higher Ahead Of FOMC Decision—Meta, Microsoft Earnings In Focus

U.S. stock futures rose on Wednesday after ending lower on Tuesday. Futures of major benchmark indic

Aclaris Therapeutics Stock Spikes In After‑Hours Session Following Major Announcement
benzinga.com
Aclaris Therapeutics Stock Spikes In After‑Hours Session Following Major Announcement

Aclaris Therapeutics Inc (NASDAQ: ACRS) surgged 21.94% in after-hours trading on Tuesday after posi

benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session

benzinga.com
Aclaris Therapeutics Reveals Top-Line Results from Open-Label Phase 2a Trial of ATI-2138; Primary E

WAYNE, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-s

benzinga.com
Piper Sandler Assumes Aclaris Therapeutics at Overweight, Announces Price Target of $6

Piper Sandler analyst Biren Amin assumes Aclaris Therapeutics (NASDAQ:ACRS) with a Overweight rat

benzinga.com
HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $16 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS)

benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session

This Arista Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
benzinga.com
This Arista Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wedne

benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session

benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session

benzinga.com
Aclaris Therapeutics And 1 Other Stock Under $5 Insiders Are Buying

benzinga.com
Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day

Shares of WD-40 Company (NASDAQ: WDFC) rose sharply during Wednesday’s session after the company rep

benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session

benzinga.com
Earnings Scheduled For May 8, 2023

Companies Reporting Before The Bell • HNI (NYSE:HNI) is likely to report quarterly loss at $0.03 pe

benzinga.com
Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason

benzinga.com
Why Rivian Automotive Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday'

Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) jumped 99% to $1.3195 after the company announ

benzinga.com
Stocks That Hit 52-Week Lows On Monday

  On Monday, 36 companies set new 52-week lows.

benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022

benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2022

Upgrades

benzinga.com
Stocks That Hit 52-Week Highs On Thursday

    Thursday morning saw 168 companies set new 52-week highs.

benzinga.com
52 Weeks High Article 0.7186450125908432

  Stocks That Hit 52-Week Highs On Monday Before 10 a.m. ET on Monday, 136 companies hit new 52-we